Evidence map›Paper›PMID 38814399›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Messenger RNA Lipid-Based Nanoparticles: Optimization of Formulations in the Lab.

Christophe Delehedde, Ivan Ciganek, Nabila Laroui, Nathalie Rameix, Federico Perche, Chantal Pichon

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christophe DeleheddeInnovative Therapies & Nanomedicine, Centre de Biophysique Moléculaire CNRS UPR01, Orléans, France.
Ivan CiganekInnovative Therapies & Nanomedicine, Centre de Biophysique Moléculaire CNRS UPR01, Orléans, France.
Nabila LarouiInnovative Therapies & Nanomedicine, Centre de Biophysique Moléculaire CNRS UPR01, Orléans, France.
Nathalie RameixSanofi R&D, Integrated Drug Discovery, Chilly-Mazarin, France.
Federico PercheInnovative Therapies & Nanomedicine, Centre de Biophysique Moléculaire CNRS UPR01, Orléans, France.
Chantal PichonInnovative Therapies & Nanomedicine, Centre de Biophysique Moléculaire CNRS UPR01, Orléans, France. chantal.pichon@cnrs.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the large variety of messenger RNA (mRNA) delivery systems, those developed with lipid-based formulations were the most widely used and efficient. In our lab, we produced different mRNA formulations made with liposomes, hybrid lipid polymer, and lipid nanoparticles. Our formulations were made with lipids bearing imidazole groups that trigger the endosomal escape of nanoparticles once protonated inside the mild acidic milieu of endosomes upon their cell uptake. Herein, we describe protocols that we used to produce, optimize, and characterize those formulations. The transfection efficiency is influenced by various factors including the physicochemical parameters of the nanoparticles, their efficiency to be internalized in cells, and their intracellular routing as well as their capacity to induce immune system sensors. We provide details on how to quantify the amount of mRNA nanoparticles uptake by cells and evaluate the acidity of the intracellular compartments where they are located, to investigate the endosomal escape, and to assess the activation of innate immune sensors as phosphorylation of PKR hampering mRNA translation.

Indexed as

LipidsNanoparticlesRNA, MessengerEndosomesHumansLiposomesTransfectionLipidsLiposomesRNA, MessengerCell uptakeLipoplexesLipopolyplexesLNPmRNA transfection

Identifiers

PMID38814399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.